Lv2
108 积分 2024-02-05 加入
Intracellular fatty acid levels differentially impact target silencing by FDA-approved siRNA drugs
17小时前
待确认
Zilebesiran: A Novel RNA Interference Therapeutic for Hypertension
1个月前
已关闭
Angiopoietin-like-protein 3 inhibition: a key to silencing residual lipid risk?
2个月前
已关闭
Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial
2个月前
已完结
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
2个月前
已完结
Prediction of Interspecies Translation for Targeting Delivery Coefficients of GalNAc-siRNA Silencing Apolipoprotein C-III Using a Mechanistic Minimal Physiologically Based Pharmacokinetic/Pharmacodynamic Model
2个月前
已完结
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation
3个月前
已完结
Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial
3个月前
已完结
Pharmacokinetics, pharmacodynamics and safety profile of SKB336, a selective inhibitor of coagulation factor XI/XIa in healthy subjects
3个月前
已完结
Pharmacokinetics, pharmacodynamics and safety profile of SKB336, a selective inhibitor of coagulation factor XI/XIa in healthy subjects
3个月前
已完结
皖公网安备34019202002308
